Core Viewpoint - The company expects to achieve a net profit of 70 million yuan for the year 2025, marking a turnaround from a loss of 170.28 million yuan in the previous year before restructuring and a loss of 138.75 million yuan after restructuring [1] Financial Performance - The anticipated net profit attributable to shareholders is 70 million yuan, compared to a loss of 170.28 million yuan in the same period last year before restructuring [1] - After restructuring, the company reported a loss of 138.75 million yuan, indicating a significant improvement in financial performance [1] - The net profit after deducting non-recurring gains and losses is expected to be 20 million yuan [1] Key Factors for Performance Change - The primary reason for the performance change is the completion of a major asset sale in January 2025, which involved divesting the lubricating oil production business [1] - The restructuring generated an investment income of 48.46 million yuan [1] - Improved management of accounts receivable led to the reversal of bad debt provisions [1]

突发公告，终止筹划重大资产重组。 *ST生物（000504）1月22日晚间公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股 权收购意向协议的提示性公告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限 合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司 51%股权。本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公 司与交易各方签署了《股权收购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，终止本次交易系公司与相关各方经充分沟通、审慎分析及友好协商后作出的决定，各方就 本次交易终止无需承担任何违约责任。本次重大资产重组的终止，不会对公司现有生产经营活动、财务 状况产生重大不利影响。目前公司生产经营秩序正常，本次交易的终止不存在损害公司及 ...

以岭药业(002603.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润12亿元至13亿 元，扭亏为盈;扣除非经常性损益后的净利润12亿元至13亿元。 2025年，公司营业收入同比实现恢复性增长。同时，公司全面强化预算管理，建立全链条成本控制体 系，实现提质增效，利润率水平提升明显。 ...

Core Viewpoint - The company, Guanghua Technology, is expected to turn a profit in 2025, with a projected net profit attributable to shareholders ranging from 85 million to 120 million yuan, compared to a loss of 204.9472 million yuan in the same period last year [1] Financial Performance - The projected net profit after deducting non-recurring items is estimated to be between 80 million and 115 million yuan, compared to a loss of 164.155 million yuan in the previous year [1] - The basic earnings per share are forecasted to be between 0.18 yuan and 0.26 yuan, while the previous year recorded a loss of 0.51 yuan per share [1] Business Development - The improvement in performance is attributed to the company's expansion into specialized chemicals and PCB (Printed Circuit Board) business, as well as a reduction in losses in the new energy sector [1] - The company is also focusing on cost reduction and efficiency enhancement initiatives [1]

Core Viewpoint - The company expects a significant turnaround in its financial performance for the fiscal year 2025, projecting a net profit attributable to shareholders between 31 million and 46 million yuan, marking a substantial increase compared to a loss of 23.41 million yuan in the previous year, representing a growth of 232.44% to 296.52% [1] Financial Performance - The anticipated net profit for 2025 is projected to be between 31 million and 46 million yuan, indicating a strong recovery from the previous year's loss [1] - The expected net profit after deducting non-recurring items is estimated to be between 20 million and 30 million yuan, reflecting a year-on-year growth of 78.16% to 167.24% [1] Factors Contributing to Growth - The company's performance improvement is attributed to a focus on its core business, market expansion, and cost reduction efforts [1] - An increase in non-recurring gains during the current period has also contributed to the anticipated financial results [1]

人民财讯1月22日电，以岭药业（002603）1月22日发布业绩预告，预计2025年归母净利润为12亿元—13 亿元，上年同期亏损7.25亿元。2025年，公司管理层保持战略定力，着眼长远发展，外拓市场，内抓管 理，营业收入同比实现恢复性增长。同时，公司全面强化预算管理，建立全链条成本控制体系，实现提 质增效，利润率水平提升明显。 ...

人民财讯1月22日电，博腾股份（300363）1月22日披露业绩预告，预计2025年归母净利润8000万元— 1.05亿元，同比扭亏为盈，上年同期亏损2.88亿元。报告期内，盈利增长的主要驱动因素为随着营业收 入的稳步增长，业务规模效应逐步显现；公司坚持推进降本增效、精益运营等举措带来运营效率提升， 公司整体毛利率较去年同比提升，费用大盘保持稳中有降；随着公司业务恢复增长，公司资产的使用效 率逐步提升，基于初步减值测试，公司本期资产减值损失预计将同比大幅减少。 ...

Core Viewpoint - The company, Daming City (600094.SH), is expected to achieve a net profit attributable to shareholders of approximately 140 million to 165 million yuan for the fiscal year 2025, marking a turnaround from losses in the previous year [1] Financial Performance - The estimated net profit for 2025 represents a significant improvement compared to the previous year, indicating a return to profitability [1] - The projected net profit, excluding non-recurring gains and losses, is expected to be around 135 million to 160 million yuan for the same period [1]

Core Viewpoint - The company Nanjing Panda announced an expected net profit attributable to the parent company of approximately 10 to 15 million yuan for the year 2025, a significant turnaround from a loss of 188.85 million yuan in the same period last year, indicating a return to profitability [1] Financial Performance - The projected net profit for 2025 is estimated to be between 10 million and 15 million yuan, compared to a loss of 188.85 million yuan in the previous year, marking a notable improvement [1] - The expected non-recurring net profit is projected to be between -25.9 million and -25.4 million yuan, compared to a loss of 20.23 million yuan in the same period last year [1] Reasons for Performance Change - The primary reason for the performance change is the gain from the disposal of equity interests in joint ventures [1] - The transformation towards intelligent manufacturing and other business areas has not met expectations, compounded by intense market competition [1] - The company has also made provisions for impairment losses on related assets [1]

Group 1 - The company expects a positive net profit for the year 2025, indicating a turnaround from previous losses [1] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The forecast has not been audited by a registered accounting firm, but preliminary discussions have been held with the auditors without major disagreements [2][3] Group 2 - The improvement in performance is attributed to the sale of 100% equity in the subsidiary, Jian Architecture, and related design business assets, which has reduced losses in the design business compared to the previous year [2] - The company has strengthened the management of accounts receivable, leading to a significant reduction in impairment losses and improved collection efficiency [2]